



For Immediate Release

Argos Therapeutics to Discuss Automated Manufacturing Process for its Arcelis™ Personalized Immunotherapy Platform

**-Presentation at the Cambridge Healthtech Institute's Advances in Cancer
Vaccines Conference-**

DURHAM, N.C. – August 11, 2008 – Argos Therapeutics today announced that Dr. Fred Miesowicz, Ph.D., Chief Operating Officer, will present details on the Company's automated manufacturing process for its Arcelis™ platform, a technology for creating personalized immunotherapies for HIV, other infectious diseases, and cancer. The presentation will take place on August 14, 2008 at the Cambridge Healthtech Institute's conference on Advances in Cancer Vaccines, part of the ImVacS Immunotherapeutics and Vaccine Summit, in Cambridge, MA.

Dr. Miesowicz's presentation will address automated systems for delivering personalized, RNA-loaded, dendritic cell-based immunotherapies on a commercial scale. Automated devices for cellular and RNA processing would have the potential for broad applicability across disease indications amenable to cell-based immunotherapy. Argos has developed working prototypes of equipment capable of automating both cellular and RNA processing. The automated system includes three standalone units: an RNA processing unit and two cellular processing units that use functionally closed disposables. Development advantages for this approach include that it is commercially feasible, involves routine clinical procedures, provides years of therapy with a single production run, and benefits from a clear regulatory path. These automated devices produce autologous immunotherapies at higher throughput and with a lower cost of goods versus manual processing methods.

Additional details on the Advances in Cancer Vaccines conference can be found at <http://www.healthtech.com/imt/overview.aspx?c=551>.

About Argos Therapeutics, Inc.

Argos is an immunotherapy company developing new treatments for cancer, infectious and autoimmune diseases, and transplantation rejection. The Company has generated multiple platform technologies and a diverse pipeline of products based on its expertise in the biology of dendritic cells - the master switch that turns the immune system on or off.

www.argostherapeutics.com

Contacts:

Jennifer Greenleaf
MacDougall Biomedical Communications

(781) 235-3060

Jeff Abbey
Argos Therapeutics
(919) 287-6308
#